Characteristics of the incidence of hepatitis B and C in the constituent entities of the Far Eastern Federal District


DOI: https://dx.doi.org/10.18565/epidem.2023.13.1.12-7

Bazykina E.A., Kotova V.O., Trotsenko O.E., Balakhontseva L.A.

Khabarovsk Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Khabarovsk, Russia
Objective. To assess the incidence of hepatitis B (HB) and C (HC) and its trend in the Far Eastern Federal District (FEFD).
Materials and methods. The authors used data on the incidence of HB and HС in Federal Statistical Observation Form No. 2 «Information on infectious and parasitic diseases» and state reports «On the state of sanitary and epidemiological well-being of the population in the Russian Federation» over 2014–2020.
Results. The incidence of acute HB and HC (AHB and AHC) in the FEFD in 2020 turned out to be twice less than the average Russian values: 0.15 cases of AHB and 0.39 cases of AHC per 100,000 population, while it in the Russian Federation was an average of 0.35 and 0.66 per 100,000 population, respectively. The trend in the incidence of AHC was shown to be correlated with a decrease in the incidence of drug addiction in the FEFD. The overall incidence of chronic HB in the FEFD was slightly higher than that detected in the Russian Federation (5.06 versus 4.36 per 100,000 population). There were no significant differences between the incidence rates of CHC in the FEFD and in the Russian Federation: the rates were 16.82 and 16.70 per 100,000 population, respectively. A reduction in the incidence of HB and HC in 2020 was noted in both the FEFD and in the whole of the Russian Federation.
Conclusion: It is necessary to continue monitoring the incidence of contact HB and HC, the decline in which in 2020 was likely to be temporary due to the redistribution of the forces of healthcare to combat COVID-19.
Keywords: COVID-19 pandemic, Far Eastern Federal District, viral hepatitis B and C, epidemic situation, incidence
Read entire article

Literature

1. ВОЗ. Информационный бюллетень. Гепатит В. 2021. https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-b


[WHO. Fact sheet. Hepatitis B. 2021]. (In Russ.). https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-b


2. ВОЗ. Информационный бюллетень. Гепатит С. 2021, ВОЗ. https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c


[WHO. Fact sheet. Hepatitis C. 2021]. (In Russ.). https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c


3. Высоцкая В.С., Коломиец Н.Д., Гасич Е.Л., Ханенко О.Н., Тонко О.В., Глинская И.Н. и др. Характеристика эпидемического процесса гепатита С на территории Республики Беларусь. Эпидемиология и Вакцинопрофилактика 2020; 19(6): 48–55. DOI: 10.31631/2073-3046-2020-19-6-48-55


Vysotskaya V.S., Kolomiets N.D., Gasich E.L., Hanenko O.N., Tonko O.V., Glinskaya I.N., et al. [Characteristics of Hepatitis C Epidemic Process in the Republic of Belarus]. Epidemiology and Vaccinal Prevention. 2020;19(6):48-55. (In Russ.). DOI: 10.31631/2073-3046-2020-19-6-48-55


4. Mahmud S., Al Kanaani Z., Abu-Raddad L.J. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect. Dis. 2019; 19(1): 1-11. DOI:10.1186/s12879-019-4403-7


5. Gao Y., Yang J., Sun F., Zhan, S., Fang, Z., Liu, X. et al. Prevalence of Anti-HCV Antibody Among the General Population in Mainland China Between 1991 and 2015: A Systematic Review and Meta-analysis. Open. Forum Infect. Dis. 2019; 6(3): ofz040. DOI: 10.1093/ofid/ofz040


6. Коноплева М.В., Борисова В.Н., Семененко Т.А., Крымский М.А. Проблемы современной стратегии вакцинации против гепатита В. Эпидемиология и Вакцинопрофилактика 2017; 16(4): 58–63. DOI: 10.31631/2073-3046-2017-16-4-58-63


Konopleva M.V., Borisova V.N., Semenenko T.A., Krymskij M.A. [Problems of the Current Vaccination Strategy against Hepatitis B]. Epidemiology and Vaccinal Prevention. 2017;16(4):58-63. (In Russ.). DOI: 10.31631/2073-3046-2017-16-4-58-63


7. Чуланов В.П., Семененко Т.А., Карандашова И.В., Комарова С.В., Костюшев Д.С., Суслов А.П., Волчкова Е.В. Современный взгляд на проблему выбора вакцины против гепатита В. Эпидемиология и Вакцинопрофилактика 2017; 16(4): 65–72. DOI: 10.31631/2073-3046-2017-16-4-65-72


Chulanov V.P., Semenenko T.A., Karandashova I.V., Komarova S.V., Kostyushev D.S., Suslov A.P., Volchkova E.V. Modern View on the Problem of Choosing a Vaccine against Hepatitis B. Epidemiology and Vaccinal Prevention. 2017; 16(4): 65–72. (In Russ.). DOI: 10.31631/2073-3046-2017-16-4-65-72


8. Титаренко Р.В. Особенности наркоситуации и проблемы профилактики наркомании среди российских подростков. Гуманитарные, социально-экономические и общественные науки 2015; 1(11-1): 191–4.


Titarenko R.V. [Features of the drug situation and the problems of drug abuse prevention among Russian teenagers]. Humanities, social-economic and social sciences 2015; 1(11-1): 191–4. (In Russ.).


9. Эсауленко Е.В., Дземова А.А., Трифонова Г.Ф., Бушманова А.Д., Новак К.Е., Огурцова С.В. и др. Гепатит С в России и Северо-Западном федеральном округе: итоги первого этапа глобальной программы элиминации инфекции. ВИЧ-инфекция и иммуносупрессии. 2021; 13(3): 40–51. DOI: 10.22328/2077-9828-2021-13-3-40-51


Esaulenko E.V., Dzemova A.A., Trifonova G.F., Bushmanova A.D., Novak K.E., Ogurtsova S.V. et al. [Hepatitis С in Russia and the Northwest federal region of Russia: results of the first stage the global programme of infection elimination]. HIV Infection and Immunosuppressive Disorders. 2021; 13(3): 40–51. (In Russ.). DOI: 10.22328/2077-9828-2021-13-3-40-51


10. Кульчавеня Е.В. Внелегочный туберкулез во время пандемии COVID-19: особенности выявления и течения. Consilium Medicum 2021; (7): 585–9. DOI: 10.26442/20751753.2021.7.201134


Kulchavenia E.V. Extrapulmonary tuberculosis during the COVID-19 pandemic: features of detection and course. Consilium Medicum. 2021; 23 (7): 585–9. (In Russ.). DOI: 10.26442/20751753.2021.7.201134


11. Filardo T.D., Feng P.J., Pratt R.H., Price S.F., Self J.L. Tuberculosis ‒ United States, 2020. Morb. Mortal. Wkly Rep. 2021; 70: 409–14. DOI: http://dx.doi.org/10.15585/mmwr.mm7012a1


12. Чернусь Н.Ю., Кедрова А.Г., Красильников С.Э., Иванин­ский О.И. Особенности оказания онколо­гической помощи в условиях пандемии COVID- 19: взгляд юриста и клинициста. Опухоли женской репродуктивной системы 2020; 116(1): 85–90 DOI: 10.17650/1994-4098-2020-16-1-85-90


Chernus N.Yu., Kedrova A.G., Krasilnikov S.E., Ivaninskiy O.I. Characteristics of oncological care in the reality of COVID-19 pandemic: views of a lawyer and a clinician. Tumors of female reproductive system. 2020; 16(1): 85–90. (In Russ.). DOI: 10.17650/1994-4098-2020-16-1-85-90


About the Autors

Elena A. Bazykina, Researcher, Khabarovsk Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Khabarovsk, Russia; alyonaf@yandex.ru; https://orcid.org/0000-0002-5695-6752
Valeria O. Kotova, Head, Laboratory for Prevention of Viral Hepatitis and AIDS, Khabarovsk Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Khabarovsk, Russia; adm@hniiem.ru; https://orcid.org/0000-0001-9824-7025
Olga E. Trotsenko, MD, Director, Khabarovsk Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Khabarovsk, Russia; trotsenko_oe@hniiem.ru; https://orcid.org/0000-0003-3050-4472
Lyudmila A. Balakhontseva, Head, MD, Far Eastern District Center for AIDS Prevention and Control, Khabarovsk Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Khabarovsk, Russia; adm@hniiem.ru; https://orcid.org/0000-0002-3209-7623


Similar Articles

Back to Content

Бионика Медиа